Goto

Collaborating Authors

 effectiveness


Mind-altering substances are (still) falling short in clinical trials

MIT Technology Review

Placebo and "knowcebo" effects are a problem. But they can also help people feel better. This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin--which is found in magic mushrooms--are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over the last decade, we've seen scientific interest in these drugs explode. But most clinical trials of psychedelics have been small and plagued by challenges.



Self-Retrieval: End-to-End InformationRetrieval withOneLargeLanguageModel

Neural Information Processing Systems

The rise of large language models (LLMs) has significantly transformed both the construction and application of information retrieval (IR) systems. However, current interactions between IR systems and LLMs remain limited, with LLMs merely serving as part of components within IR systems, and IR systems being constructed independently of LLMs. This separated architecture restricts knowledge sharing and deep collaboration between them. In this paper, we introduce Self-Retrieval, a novel end-to-end LLM-driven information retrieval architecture.